Biobanking and Cryopreservation of Stem Cells

Maria Carolina Oliveira Rodrigues, Trenton Lippert, Hung Nguyen, Sussannah Kaelber, Paul R. Sanberg, Cesar V. Borlongan, Rodrigues, Maria Carolina Oliveira, Lippert, Trenton, Nguyen, Hung, Kaelber, Sussannah, Sanberg, Paul R., Borlongan, Cesar V.

Feridoun Karimi-Busheri, Michael Weinfeld

Accumulating evidence has demonstrated that menstrual blood stands as a viable source of stem cells. Menstrual blood-derived stem cells (MenSCs) are morphologically and functionally similar to cells directly extracted from the endometrium, and present dual expression of mesenchymal and embryonic cell markers, thus becoming interesting tools for regenerative medicine. Functional reports show higher proliferative and self-renewal capacities than bone marrow-derived stem cells, as well as successful differentiation into hepatocyte-like cells, glial-like cells, endometrial stroma-like cells, among others. Moreover, menstrual blood stem cells may be used with increased efficiency in reprogramming techniques for induced Pluripotent Stem cell (iPS) generation. Experimental studies have shown successful treatment of stroke, colitis, limb ischemia, coronary disease, Duchenne's muscular atrophy and streptozotocin-induced type 1 diabetes animal models with MenSCs. As we envision an off-the-shelf product for cell therapy, cryopreserved MenSCs appear as a feasible clinical product. Clinical applications, although still very limited, have great potential and ongoing studies should be disclosed in the near future.